PT-141 (Vyleesi) for Women: The Complete Honest Guide to the Only FDA-Approved Desire Peptide

PT-141 — bremelanotide, marketed as Vyleesi — is the only FDA-approved peptide for female sexual desire, and one of the most misunderstood compounds in this whole space. It is approved for premenopausal women with hypoactive sexual desire disorder (HSDD), it works through a mechanism unlike anything else in the field, and it has a set of tradeoffs the marketing has never quite captured. This is the complete, honest read for women considering it.

What PT-141 Actually Is

Bremelanotide is a synthetic melanocortin receptor agonist — it binds primarily to MC4 receptors in the central nervous system. The mechanism has nothing to do with blood flow, hormones, or peripheral sexual response. It acts on the brain circuits that govern sexual desire itself. That is what makes it unusual: every other approved sexual-medicine drug on the market (sildenafil, tadalafil, vardenafil) targets peripheral vasodilation. PT-141 targets desire directly at the central-nervous-system level.

Vyleesi was FDA-approved in June 2019 for premenopausal women with HSDD acquired (not lifelong) and generalized (not situational). It is self-administered subcutaneously, typically about 45 minutes before anticipated sexual activity. It is not a daily medication.

What the Trials Actually Showed

The pivotal RECONNECT trials enrolled women meeting the acquired-generalized-HSDD criteria. Treatment effect on the primary desire and distress endpoints was statistically significant but modest in absolute terms — a fact worth internalizing before starting. This is not a compound that transforms every user. It is a compound that produces a measurable, meaningful improvement in a subset of appropriate candidates.

The Side Effects You Need to Actually Know About

Blood pressure elevation occurs briefly after each dose, which is why PT-141 is not appropriate for women with uncontrolled hypertension or established cardiovascular disease.

Who It Is For — and Who It Is Not

PT-141 is appropriate for premenopausal women whose HSDD is acquired and generalized, who have no untreated hypertension or CVD, who understand the nausea risk, and who are prepared to tolerate the possibility of skin hyperpigmentation. It is not appropriate for postmenopausal women (efficacy and safety not established in this population), women with cardiovascular contraindications, or women whose sexual concerns are relational, situational, or fundamentally not desire-focused.

The Gray-Market Situation

PT-141 is widely sold by research-peptide vendors as "PT-141" or "bremelanotide," typically at lower cost than the approved Vyleesi product. The vendor market is where nearly all of the male-use conversation happens (bremelanotide is not FDA-approved for men, but is used off-label from research supply). For women, the calculation is different: an approved formulation exists, and the FDA's July 2026 testimony about peptide identity standardization — different active molecules being sold under the same name — applies with particular force to a compound acting on central-nervous-system melanocortin receptors. This is not a safe compound to guess about.

The Approved-Product Path

Vyleesi is prescribed by licensed providers, dispensed through specialty pharmacies, and comes with the identity, dosing, and manufacturing controls research-vendor compounds do not have. It is expensive without insurance coverage. Some telehealth providers include it in their sexual-medicine offerings; Veritide's provider comparisons can help identify which programs actually stock the approved formulation versus routing patients toward off-label alternatives.

The Non-Peptide Options Worth Knowing

For premenopausal HSDD, flibanserin (Addyi) is the other FDA-approved oral option, with a different mechanism (serotonergic) and a different side-effect profile (drowsiness, alcohol interactions). For postmenopausal women, testosterone therapy is the evidence-based option for HSDD in many international guidelines, though FDA-approved formulations for women are limited in the US market. A women's-health-oriented clinician can help sort the options; PeptideOnline's PT-141 profile covers the mechanism science in more detail.